Clinical Trial Update: Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on entospletinib plus vincristine in relapsed/refractory B-cell non-Hodgkin lymphoma; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Entospletinib (entospletinib)
• Vincristine (vincristine)

Snippet

Sponsor: Gilead Sciences | Conditions: Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-04-17